ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors-Reference-Cited by-同舟云学术

ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors

Published:2024-08-14 Issue:1 Volume:148 Page:
ISSN:1432-0533
Container-title:Acta Neuropathologica
language:en
Short-container-title:Acta Neuropathol

Author:

Zhang Kevin Y.,Parker Megan,Weber-Levine Carly,Kalluri Anita,Gonzalez-Gomez Ignacio,Raabe Eric,Dudley Jonathan C.,Gocke Christopher,Lin Ming-Tseh,Zou Ying,Sherief Mohamed,Kamson David O.,Holdhoff Matthias,Mukherjee Debraj,Croog Victoria,Schreck Karisa C.,Rincon-Torroella Jordina,Bettegowda Chetan,Eberhart Charles G.,Bale Tejus,Lucas Calixto-Hope G.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00401-024-02785-z.pdf

Reference10 articles.

1. Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR et al (2013) Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 210:2641–2659. https://doi.org/10.1084/jem.20131141

2. Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J et al (2017) OncoKB: a precision oncology knowledge base. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00011

3. Filipski K, Braun Y, Zinke J, Roller B, Baumgarten P, Wagner M et al (2019) Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. Acta Neuropathol 138:331–334. https://doi.org/10.1007/s00401-019-02025-9

4. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci M-J, Birnbaum D (2012) Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 5:12. https://doi.org/10.1186/1756-8722-5-12

5. Jain SU, Do TJ, Lund PJ, Rashoff AQ, Diehl KL, Cieslik M et al (2019) PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. Nat Commun 10:2146. https://doi.org/10.1038/s41467-019-09981-6